SciSparc's NeuroThera Labs Secures Patent for Obesity and Fatty Liver Therapy
Event summary
- NeuroThera Labs, a SciSparc subsidiary, published an international patent for a novel combination therapy targeting obesity and fatty liver disease.
- The therapy combines Clearmind’s MEAI platform with NeuroThera’s PEA, aiming to offer a non-hallucinogenic alternative to GLP-1 agonists.
- The global weight loss drugs market is projected to grow from $37 billion in 2025 to $226 billion by 2035.
- SciSparc holds a 75% controlling interest in NeuroThera Labs.
The big picture
The patent highlights the growing demand for innovative, non-hallucinogenic treatments in the obesity and liver health space. With the global weight loss drugs market expanding rapidly, this collaboration positions SciSparc to capitalize on a significant unmet need. The therapy's potential to offer a safer and more cost-effective alternative to GLP-1 agonists could reshape the competitive landscape.
What we're watching
- Market Disruption
- How the MEAI-PEA combination will challenge existing GLP-1 agonists in the obesity and fatty liver disease market.
- Regulatory Pathway
- The pace at which the therapy advances through clinical trials and secures regulatory approval.
- Commercialization Strategy
- Whether SciSparc can leverage its controlling interest in NeuroThera to accelerate the therapy's market entry.
Related topics